Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours Abstract #1850

Introduction: Hypoxia in human tumours is associated with a poor prognosis and is characterized by the stabilization of HIF1α, upregulation of VEGF, and a high microvessel density (MVD). Interestingly, although pancreatic neuroendocrine tumours (pNETS) showing hypoxia signalling also have a poor prognosis, they paradoxically display a low MVD. We hypothesized that this paradoxon might be explained by alternative splicing of VEGF.
Aim(s): Our aim was to analyze the microvessel architecture in pNETs with high and low MVD and to investigate the role of VEGF-A splicing in these tumours as well as in the human pNET cell lines Bon1 and QGP1.
Materials and methods: In each five pNETs with high and low MVD microvessel architecture was examined using 3D reconstruction. VEGF-A splicing was examined in the same tumours as well as in Bon1 and QGP1 under normoxic and hypoxic conditions.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Anja Maria Schmitt
Keywords: pNET, VEGF

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1111 Autophagy as a Possible Mechanism of Resistance in pNET Treatment
Introduction: Pancreatic neuroendocrine tumor (pNET) patients often display primary or secondary resistance to Sunitinib, an anti-angiogenic multi-receptor tyrosine kinase inhibitor which has been approved for the treatment of late stage pNETs. In late cancer stage autophagy often has a tumor promoting role. Sunitinib might additionally activate autophagy through inhibition of mTOR or induction of hypoxia.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tabea Wiedmer
#1638 3D Primary Cell Culture: A New Promising Preclinical Model for Pancreatic Neuro-Endocrine Tumors (pNETs).
Introduction: The lack of adequate in vitro and in vivo preclinical models has hampered the identification of novel treatment options and the development of personalized therapy selection for pNET patients.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Ilaria Marinoni
#856 DAXX and ATRX Loss Defines Chromosomal Instability and Poor Outcome in Pancreatic NET
Introduction: Chromosomal Instability (CIN) has been reported in pancreatic neuroendocrine tumors (pNETs) with poor outcome. However, no specific genetic background has been associated with CIN. Whole exome sequencing revealed mutations in DAXX (Death domain associated protein gene) and ATRX (ATR-X gene) in 40% of pNETs. DAXX and ATRX mutations in pNETs are associated with Alternative Lengthening of Telomeres (ALT) activation.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: PhD Ilaria Marinoni
Keywords: pNET, Daxx, Atrx, ALT, CIN
#1034 Identification of Novel and Pathological Feature of Angiostatic Microvasculature in Liver Metastatic Pancreatic Neuroendocrine Tumors and Its Clinical Implication
Introduction: Microvasculature of liver metastatic pancreatic neuroendrocrine tumors (LM-PNETs) are unknown.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Xu Han
Authors: Han X, Hexige S, Lou W, ...
#1780 PD-L1 Is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)
Introduction: Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, interacting with two ligands, PD-L1 and PD-L2. The former is expressed in many human cancers and is used as a selection criterion for indication of checkpoint inhibitor therapies. PD-L1 is also a potential target for checkpoint inhibitors in pNET therapy, however no data on prevalence of PD-L1 expression and potential associations to clinico-pathologic features is available.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MMed Charalampos Saganas